Crise des opioïdes aux États-Unis : quelles implications pour la Suisse ? [Opioid crisis in the USA: what are implications for Switzerland?]

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 18/03/2026.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_58827A409D5F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Crise des opioïdes aux États-Unis : quelles implications pour la Suisse ? [Opioid crisis in the USA: what are implications for Switzerland?]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Bertholet N., Araiedh J., Englander H.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
18/09/2024
Peer-reviewed
Oui
Volume
20
Numéro
887
Pages
1660-1663
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Warnings in Europe signal a rise in illicitly-manufactured fentanyl and other high potency synthetic opioids which could destabilize drug markets, strain health systems, and escalate harms of substance use and death. Here, we provide an overview of fentanyl in North America, drawing implications for Switzerland. Fentanyl withdrawal starts sooner, is more severe, and has worse anxiety and pain. Clinical care includes aggressive use of full agonist opioids, opioid agonist therapies (OAT) and adjunctive medications for acute withdrawal, and a need for low-threshold, readily accessible OAT to engage patients and mitigate harms. The US experience suggests the importance of widespread naloxone distribution, peer-based initiatives, early warning systems, and partnerships across patient-groups, healthcare systems, and public health.
Mots-clé
Humans, Switzerland/epidemiology, United States/epidemiology, Analgesics, Opioid/adverse effects, Analgesics, Opioid/administration & dosage, Opioid Epidemic/prevention & control, Fentanyl/adverse effects, Fentanyl/administration & dosage, Opioid-Related Disorders/epidemiology, Opioid-Related Disorders/prevention & control, Substance Withdrawal Syndrome, Naloxone/therapeutic use, Naloxone/administration & dosage
Pubmed
Création de la notice
25/09/2024 8:29
Dernière modification de la notice
04/10/2024 6:04
Données d'usage